Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Improving Islet Transplantation Outcomes With Gastrin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03746769
Recruitment Status : Recruiting
First Posted : November 20, 2018
Last Update Posted : March 5, 2019
Sponsor:
Collaborator:
University of California, Los Angeles
Information provided by (Responsible Party):
City of Hope Medical Center

Brief Summary:

This clinical study will evaluate the safety and effectiveness of Gastrin treatment with islet transplantation to help patients with difficult to control type 1 diabetes make insulin again and improve blood sugar control.

This study involves two investigational (experimental) products not yet approved by the U.S. Food and Drug Administration (FDA) as a treatment for any disease:

  1. Human allogenic islet cells (islet cells from a deceased, unrelated human donor)
  2. Gastrin-17 (Gastrin) - a hormone secreted by the gut

Islet cell transplantation involves transplanting the cells that make insulin from a pancreas of deceased organ donor to a patient with diabetes. Because there is a limited supply of donor islet cells available, this study is testing whether Gastrin injections can help make a fewer number of transplanted islets work better.

Gastrin is a natural gut hormone that is present in the pancreas during its development in the embryo but not after birth, and is believed to participate in the formation of the normal pancreas. Several studies have tried to use gastrin to help grow insulin making islet cells in laboratory experiments or after transplanting islets in laboratory animals. In early clinical trials, diabetic patients treated with gastrin and other growth factors required less insulin after 4 weeks of gastrin treatment and the effect lasted more than 12 weeks after stopping treatment, suggesting that gastrin may have increased the number of cells that make insulin.

This study will evaluate whether taking Gastrin injections following a single islet transplantation is safe, improves how well the islet transplant works and/or helps increase the number of insulin-making cells in the islets.

Qualified participants will receive treatment with a single islet transplant, followed by two rounds of gastrin treatment (twice daily injections for 30 days) just after transplant and again 6 months later. Study participants will also take anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support their health and/or the health of the transplanted islets. Participants will need to return to City of Hope in Duarte, CA for frequent follow-up visits for one year after transplant.


Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Biological: Allogenic Human Islet Cells Drug: Gastrin 17 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Improving Islet Transplantation Outcomes With Gastrin
Actual Study Start Date : February 1, 2019
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023


Arm Intervention/treatment
Experimental: Single Arm Study Biological: Allogenic Human Islet Cells
islet cells transplanted into the portal vein in the liver

Drug: Gastrin 17

Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later.

Also, anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.





Primary Outcome Measures :
  1. Proportion of subjects who are insulin independent, free from severe hypoglycemia and have HbA1c < 6.5% ("complete response") [ Time Frame: 1 year post transplant (6 months after second course of Gastrin) ]

Secondary Outcome Measures :
  1. Proportion of subjects who are free of severe hypoglycemic episodes (SHE) and have a HbA1c <7.0% ("partial response"). [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]

Other Outcome Measures:
  1. Reduction/elimination of hypoglycemia [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
  2. Reduction in daily insulin use [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
  3. Reduction of daily insulin use per 100,000 IEQ transplanted [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
  4. C-peptide/insulin secretion response to glucose/arginine stimulation and other metabolic studies. [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
  5. Incidence of treatment-related adverse events [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
  6. Incidence of a change in immunosuppression drug regimen [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
  7. The incidence of immune sensitization defined by presence of anti-HLA antibodies absent prior to transplant [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
  8. Incidence of discontinuation of immunosuppression [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
  9. Incidence of change or early discontinuation of Gastrin treatment [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]
  10. Incidence of change or early discontinuation of sitagliptin/esomeprazole supportive therapy [ Time Frame: At Month 1, Month 2.5, and Month 6 post start of each Gastrin course ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 68 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18-68 years
  2. Type 1 diabetes mellitus (documented with fasting C-peptide level of < 0.2 ng/ml before and < 0.3 ng/ml after IV administration of 1 mg of glucagon) for at least 5 years.
  3. Frequent hypoglycemia (blood glucose 54 mg/dl more than once per week) -or- Hypoglycemia unawareness (Clarke score of 4 or more). -or- One or more severe hypoglycemic episodes in 12 months preceding enrollment (see Section 3.1.4 for definition)
  4. Ability and willingness to comply with post-transplant regimen, including immunosuppression, use of reliable contraception, frequent clinic visits, testing and maintaining detailed logs of blood glucose levels, insulin doses and medications, and completing detailed follow-up studies.
  5. Ability to give informed consent.

Exclusion Criteria:

  1. Weight > 80 kg or BMI > 30
  2. Insulin requirements > 50 units/day
  3. Known sensitization to rATG
  4. Significant kidney disease (estimated GFR from serum creatinine measurement <70 ml/min, random spot urine microalbumin to creatinine ratio >300mg albumin/g creatinine)
  5. Significant hepatobiliary disease, including elevation of liver enzymes > twice the upper limit of normal for each of ALT and AST (any elevation of these enzymes will be determined), bilirubin not within normal limits, albumin < 3.5 g/dl, liver masses, portal vein thrombosis, evidence of portal hypertension, or significant, untreated gallbladder disease (i.e. gallstones)
  6. Significant cardiovascular disease, including non-correctable coronary artery disease with ejection fraction < 50% and/or recent myocardial infarction (within last 12 months); or extensive peripheral vascular disease not correctable by surgery,
  7. Evidence of active proliferative retinopathy
  8. Hypertension (140/90) despite appropriate treatment
  9. Hyperlipidemia (total cholesterol > 260 mg/dl, LDL > 160 mg/dl, and/or triglycerides > 300 mg/dl) despite appropriate treatment
  10. Anemia (Hgb < 11 g/dl) or other hematologic disorders that require medical attention
  11. WBC <3,000/l
  12. Increased risk of bleeding (platelet count < 120,000 cells/l; INR > 1.5), other chronic hemostasis disorders, or treatment with chronic anticoagulant therapy (i.e. heparin or warfarin)
  13. Recent unresolved acute infection (except for mild skin infection or nail fungal infection), or chronic infection, including tuberculosis, HIV, HBV, HCV, CMV or syphilis (RPR)
  14. EBV IgG negative
  15. Any history of malignancy, except completely resected squamous or basal cell skin cancer or in situ cancer of the cervix
  16. Active peptic ulcer disease or current therapy with proton pump inhibitor (PPI)
  17. Symptomatic gastroparesis
  18. History of gastric bypass
  19. Recent history of non-adherence to recommended medical therapy
  20. Psychiatric illness that is untreated, or likely to interfere significantly with study compliance despite treatment
  21. Previous organ/tissue transplant
  22. Presence of preformed antibodies on panel reactive antibody screening > 20%
  23. Administration of live attenuated vaccines within 60 days of enrollment.
  24. Presence of a chronic disease that must be chronically treated with contraindicated medications
  25. Use of investigational agents within four weeks of enrollment
  26. Active alcohol or substance abuse, including cigarette smoking (must be abstinent for > 3 months)
  27. Pregnant women, women intending future pregnancy, women of reproductive potential who are unable or unwilling to follow effective contraceptive measures (i.e., tubal ligation, two barrier methods, abstinence) for the duration of study treatment and for as long as they are on immunosuppressive medication, and women presently breastfeeding.
  28. Individuals without health insurance covering the cost of immunosuppression and clinical and laboratory follow-up after completion of the study
  29. Any medical condition that in the opinion of the investigator will interfere with safe participation in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03746769


Contacts
Layout table for location contacts
Contact: City of Hope Diabetes and Metabolism Research Institute 1-866-44-ISLET(1-866-444-7538) Islets@coh.org

Locations
Layout table for location information
United States, California
City of Hope Medical Center Recruiting
Duarte, California, United States, 91010
Principal Investigator: Fouad Kandeel, MD, PhD         
Sponsors and Collaborators
City of Hope Medical Center
University of California, Los Angeles
Investigators
Layout table for investigator information
Principal Investigator: Fouad Kandeel, MD, PhD City of Hope Medical Center

Additional Information:
Layout table for additonal information
Responsible Party: City of Hope Medical Center
ClinicalTrials.gov Identifier: NCT03746769     History of Changes
Other Study ID Numbers: 18156
First Posted: November 20, 2018    Key Record Dates
Last Update Posted: March 5, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by City of Hope Medical Center:
islet
islet cell
transplant
gastrin
hypoglycemia
labile diabetes
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Gastrins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs